News

Biocon Biologics expands diabetes portfolio with FDA approval for Kirsty

Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...
Capital Market on MSN5d

Biocon arm gets USFDA approval for insulin, Kirsty

Kirsty is biosimiler to Novolog. It is a rapid-acting human insulin analog indicated to improve glycemic control in adults ...
The Pharma Letter5d

FDA approves Biocon BLA for Kirsty

The US Food and Drug Administration approved, the first rapid-acting interchangeable biosimilar product, Kirsty (insulin ...
Medical Dialogues5d

Biocon Biologics expands biosimilar insulin portfolio with USFDA nod of Kirsty

Karnataka: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has received ...
Rediff Money5d

Biocon's Kirsty: USFDA Approval for Diabetes Drug

Biocon Biologics receives USFDA approval for Kirsty, an interchangeable biosimilar to NovoLog. This rapid-acting insulin ...
Trade Brains on MSN5d

Pharma stock jumps 4% after receiving USFDA approval for diabetes treatment drug

The shares of the prominent pharmaceutical company gained up to 4 percent in today's trading session after the company ...

Biocon Biologics gets USFDA nod for rapid-acting insulin

The US diabetes market presents a substantial opportunity for Biocon Biologics, with 38.4 million people living with diabetes ...
Stocktwits on MSN5d

Buy Biocon, Zydus Life For Short-Term Gains, Says SEBI RA Vinayak Gautam After Fresh Regulatory Approvals

Biocon and Zydus Lifesciences are in the spotlight with fresh regulatory approvals fueling bullish analyst sentiment and renewed retail interest. Biocon shares rose 2% on Wednesday after its ...

Biocon Biologics Expands Diabetes Portfolio With FDA Approval Of Kirstytm, The First And Only Interchangeable Rapid-Acting Insulin Aspart In The United States

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL) , a fully int ...

Should you buy Biocon shares as USFDA gives approval to diabetes drug?

Biocon share price today rose 3% after Biocon Biologics received US FDA approval for diabetes drug Kirsty, the first interchangeable biosimilar to NovoLog in the US. Get latest updates on Biocon ...
The Bakersfield Californian5d

Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only ...

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE ...